An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth

被引:14
作者
Crowder, C
Kopantzev, E
Williams, K
Lengel, C
Miki, T
Rudikoff, S [1 ]
机构
[1] NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Tumor Biol Sect, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Ras; mutation; transformation; growth factor independence;
D O I
10.1038/sj.onc.1206180
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple myeloma (MM) is an incurable plasma cell malignancy. To investigate biochemical lesions associated,with MM, we constructed an expression cDNA library from the OPM-2 human myeloma line. A highly transforming H-Ras mutant was identified by transfection analysis using NIH 3T3 cells. DNA sequencing demonstrated a single-point mutation at position 117 located in the guanine nucleotide-binding site resulting in a lysine-to-glutamic acid substitution. This mutant, H-Ras (K117E), was found to be constitutively activated in terms of GTP binding. We compared the biological effects of H-Ras (K117E) and H-Ras (G12V) in 32D murine hematopoietic progenitor cells. Whereas both Ras proteins are constitutively activated, 32D cells expressing H-Ras (G12V) are still dependent on IL-3 for survival and proliferation while cells carrying H-Ras (K117E) become IL-3 independent. Similar experiments conducted with the B9 line, an IL-6-dependent hybridoma, also demonstrated that B9/H-Ras (KI17E) became IL-6-independent. Expression of H-Ras (K117E) in the human IL-6-dependent ANBL-6 myeloma line resulted in enhanced proliferation at suboptimal concentrations of IL-6. These observations suggest that H-Ras mutations at the binding site for the GTP nucleotide ring structure may also represent activating lesions and have additional biological effects when compared to previously described Ras mutants.
引用
收藏
页码:649 / 659
页数:11
相关论文
共 56 条
[41]   AN EFFICIENT DIRECTIONAL CLONING SYSTEM TO CONSTRUCT CDNA LIBRARIES CONTAINING FULL-LENGTH INSERTS AT HIGH-FREQUENCY [J].
MIKI, T ;
MATSUI, T ;
HEIDARAN, MA ;
AARONSON, SA .
GENE, 1989, 83 (01) :137-146
[42]   MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION - STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS [J].
MILBURN, MV ;
TONG, L ;
DEVOS, AM ;
BRUNGER, A ;
YAMAIZUMI, Z ;
NISHIMURA, S ;
KIM, SH .
SCIENCE, 1990, 247 (4945) :939-945
[43]   RAS ONCOGENE MUTATION IN MULTIPLE-MYELOMA [J].
NERI, A ;
MURPHY, JP ;
CRO, L ;
FERRERO, D ;
TARELLA, C ;
BALDINI, L ;
DALLAFAVERA, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (05) :1715-1725
[44]   STRUCTURE OF THE GUANINE-NUCLEOTIDE-BINDING DOMAIN OF THE HA-RAS ONCOGENE PRODUCT P21 IN THE TRIPHOSPHATE CONFORMATION [J].
PAI, EF ;
KABSCH, W ;
KRENGEL, U ;
HOLMES, KC ;
JOHN, J ;
WITTINGHOFER, A .
NATURE, 1989, 341 (6239) :209-214
[45]  
PAQUETTE RL, 1990, ONCOGENE, V5, P1659
[46]   PRODUCTION OF HIGH-TITER HELPER-FREE RETROVIRUSES BY TRANSIENT TRANSFECTION [J].
PEAR, WS ;
NOLAN, GP ;
SCOTT, ML ;
BALTIMORE, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8392-8396
[47]  
Rawat R, 2000, BLOOD, V96, P3514
[48]   A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene [J].
Richelda, R ;
Ronchetti, D ;
Baldini, L ;
Cro, L ;
Viggiano, L ;
Marzella, R ;
Rocchi, M ;
Otsuki, T ;
Lombardi, L ;
Maiolo, AT ;
Neri, A .
BLOOD, 1997, 90 (10) :4062-4070
[49]   Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan [J].
Rowley, M ;
Liu, PC ;
Van Ness, B .
BLOOD, 2000, 96 (09) :3175-3180
[50]   Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies [J].
Sebti, SM ;
Hamilton, AD .
ONCOGENE, 2000, 19 (56) :6584-6593